Bausch Health Cos (NYSE:BHC) Shares Up 4.9% – Should You Buy?

by · The Cerbat Gem

Shares of Bausch Health Cos Inc. (NYSE:BHC – Get Free Report) were up 4.9% during mid-day trading on Tuesday . The company traded as high as $7.26 and last traded at $7.3350. Approximately 2,553,177 shares were traded during mid-day trading, a decline of 0% from the average daily volume of 2,557,288 shares. The stock had previously closed at $6.99.

Analysts Set New Price Targets

Several research analysts recently issued reports on BHC shares. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Raymond James Financial upgraded Bausch Health Cos to a “hold” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bausch Health Cos in a report on Monday, December 15th. Finally, Barclays began coverage on Bausch Health Cos in a research report on Monday, December 8th. They issued an “equal weight” rating and a $8.00 price target on the stock. Five investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.67.

Check Out Our Latest Stock Analysis on Bausch Health Cos

Bausch Health Cos Stock Down 1.3%

The company has a debt-to-equity ratio of 57.48, a current ratio of 1.30 and a quick ratio of 0.97. The stock has a market cap of $2.68 billion, a price-to-earnings ratio of 7.45 and a beta of 0.41. The firm has a 50 day simple moving average of $6.59 and a two-hundred day simple moving average of $6.62.

Institutional Investors Weigh In On Bausch Health Cos

Several large investors have recently bought and sold shares of BHC. Nuveen LLC bought a new stake in shares of Bausch Health Cos in the 1st quarter valued at $1,473,000. Quantbot Technologies LP lifted its holdings in shares of Bausch Health Cos by 387.9% during the 1st quarter. Quantbot Technologies LP now owns 21,235 shares of the company’s stock valued at $137,000 after purchasing an additional 16,883 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Bausch Health Cos in the 1st quarter valued at approximately $73,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in Bausch Health Cos by 25.4% during the 1st quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 169,407 shares of the company’s stock worth $1,099,000 after purchasing an additional 34,334 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in Bausch Health Cos during the 1st quarter worth approximately $1,055,000. Institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

(Get Free Report)

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.

Read More